Pheno Therapeutics (Pheno)– a company focused on the development of small molecule therapeutics for the treatment of neurological diseases – has announced that it has entered into an exclusive worldwide licence agreement with UCB.
It involves a preclinical small molecule programme designed to selectively modulate the activity of an undisclosed target that is expressed on human oligodendrocytes and is known to play a critical role in the biological pathway of myelination. The agreement enables Pheno to further develop, commercialise and manufacture treatments emerging from the programme.
Dhaval Patel, UCB’s chief scientific officer, commented: “Licence agreements like this are a demonstration of the value UCB scientists and our partners are creating through strong research productivity, and we are confident that Pheno, with its expertise in phenotypic screening, stem cell technology and myelin biology, will develop this preclinical programme to its full potential,”
Fraser Murray, chief executive officer at Pheno, reflected: “Pheno utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This licence allows us to accelerate a promising drug target towards clinical development.”
He added: “Together with our human neurological drug development expertise, there is significant opportunity for Pheno to fast-track this programmr towards clinical proof-of-concept studies and potentially deliver transformational drugs for the treatment of demyelination diseases.”
Meanwhile, Pheno will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialisation and UCB will receive milestones and tiered royalties on net sales. Further financial details of the agreement were not disclosed.
by John Pinching
Source: pharmatimes.com
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.